放化疗加参芪扶正注射液治疗非小细胞肺癌的临床研究  

Clinical evaluation of Shenqi Fuzheng injection in the chemo-radiotherapy in treatment of non-small cell lung cancer

作　　者：周陈华[1] 陈勇[1] 叶鸿[1] 王宝强[1] 陈华津[1] 

机构地区：[1]温州医学院附属第六医院 浙江省丽水市人民医院放疗科,浙江丽水323000

出　　处：《肿瘤研究与临床》2008年第5期316-318,321,共4页Cancer Research and Clinic

摘　　要：目的 探讨放化疗综合治疗加参芪扶正注射液治疗非小细胞肺癌(NSCLC)的疗效和毒副作用.方法 2004年6月至2006年6月,将放化疗综合治疗NSCLC 58例,随机分为两组:两组患者均先给予2个周期的NP方案作诱导化疗[长春瑞滨(NVB)25 mg/m2,第1天、第8天;顺铂(DDP)30 mg/m2,第1天至第3天],3周为1个周期;第2个周期化疗结束后开始放疗,采用常规分割,6～15 MV-X线,DT60 Gy,30次,6周完成.治疗组在放化疗期间加用参芪扶正注射液250 ml,每天1次,21 d为1个周期,2个周期为1个疗程.对照组给予一般支持治疗.两组患者在放疗结束后1周再用NP方案化疗2个周期.比较两组的临床疗效、不良反应、生活质量、免疫功能.结果 治疗组完全缓解率、部分缓解率、总有效率分别为16.7%、60.0%、76.7%;对照组分别为10.7%、50.0%、60.7%.治疗组0.5、1、2年生存率分别为96.7%、65.2%、45.0%;对照组分别为89.3%、48.0%、35.1%.两组比较差异无统计学意义(P＞0.05).两组患者的临床症状、生活质量、免疫功能改善情况比较,差异有统计学意义(P＜0.05).结论 放化疗加参芪扶正注射液综合治疗NSCLC能改善患者的临床症状、生活质量、免疫功能和减轻放化疗的不良反应,但未能提高患者的生存率.Objective To evaluate the response and toxicity of the chemo-radiotherapy assisted with Shenqi Fuzheng injection(SFI)in non-small-cell lung cancer(NSCLC).Methods 58 cases of NSCLC(from Jun.2004 to Dec.2006)were divided at random into two groups.30 cases(trial group)were given chemo-radiotherapy with Shenqi Fuzheng injection while another 28 cases(control group)only chemo-radiotherapy.The radiotherapy was carried out between two cycles of induction chemotherapy with NVB 25 mg/m2 d1,8,DDP 30 mg/m2 d1-3.The radiation dose was 60 Gy/30 f/6 W.Shenqi Fuzheng injection was used in 250 ml/d,for 21days as one cycle and after 7 day intervals, given another one cycle.The cycles of same regimen chemotherapy were given again after one week when the radiotherapy had been completed.Results Shortterm therapeutic effectiveness.the rates of complete remission and partial remission as well as the overall effective rates in patients of the trial group and control group were 16.7%,60.0%and 76.7%,and 10.7%,50.0%and 60.7%,respectively,the differences between two groups be not significant(P＞0.05).The 0.5,1,2year survival rates in patients of the trial group and control group were 96.7%,65.2%,45.0%and 89.3%,48.0%,35.0%,respectively,the differences between two groups were not significant(P＞0.05).Shenqi Fuzheng injection was shown to have changes in chemo-radiotherapy effects on clinical symptom,quality of life (QOL)and immune function and toxicity in the treatment of patients with NSCLC(P＜0.05).Conclusion Shenqi Fuzheng injection is shown to have changes in ehemo-radiotherapy effects on clinical symptom,QOL and immune function and toxicity in the treatment of patients with NSCLC,but it could not increase survival rate of the patients.

关 键 词：癌 非小细胞肺 放射治疗 抗肿瘤联合化疗方案 

分 类 号：R734[医药卫生—肿瘤]